Skip to main content

MPM Capital — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

49
Companies
$3.9B
Total invested
$90.3M
Avg. check
17
Industries
Biotechnology 21Health Care 11Therapeutics 11Medical 9Pharmaceutical 8Life Science 3+11 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 49
Firefly Bio
February 2024

Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.

Biotechnology · San Francisco$94.0M Series A
Deka Biosciences
December 2023

Early stage biotechnology company

Biotechnology · Germantown$29.9M Series Unknown
AstronauTx
October 2023

AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes.

Biotechnology · Reading$58.7M Series A
ReNAgade Therapeutics
May 2023

ReNAgade Therapeutics focuses on the boundless potential of RNA therapeutics to treat disease.

Biotechnology · Cambridge$300.0M Series A
Photys Therapeutics
September 2022

Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein modifications.

Biotechnology · Cambridge$75.0M Series A
Orna Therapeutics
August 2022

Orna Therapeutics is a biotechnology company that specializes in fully engineered circular RNA therapeutics to treat various diseases.

Biotechnology · Cambridge$221.0M Series B
Werewolf Therapeutics
May 2022

Werewolf Therapeutics operates as an oncology biotherapeutics company.

Biotechnology · Cambridge$50.0M Post Ipo Secondary
Oncorus
April 2022

Oncorus is an immuno-oncology company developing oncolytic viruses to fight cancer.

Biotechnology · Cambridge$20.0M Post Ipo Debt
SiO2 Materials Science
December 2021

SiO2 Materials Science is a plastic container designing company.

Manufacturing · Auburn$205.0M Debt Financing
CODA Biotherapeutics
December 2021

CODA Biotherapeutics develops a chemogenetic platform designed to modulate neuronal activity.

Biotechnology · South San Francisco$28.0M Series Unknown
Cerecor
August 2021

Cerecor discovers, develops and commercializes neuroscience drugs.

Biopharma · Baltimore$10.0M Post Ipo Debt
BioIntervene
June 2021

BioIntervene is engages in drug discovery and development.

Biotechnology · San Diego$5.6M Series Unknown
Tizona Therapeutics
July 2020

Tizona develops next-generation immunotherapies

Biotechnology · South San Francisco$300.0M Corporate Round
Triplet Therapeutics
December 2019

Triplet is developing transformative therapies that treat repeat expansion disorders at their source.

Biotechnology · Cambridge$49.0M Series A
Twentyeight-Seven Therapeutics
May 2019

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.

Biotechnology · Cambridge$15.0M Series A
TriNetX
March 2019

TriNetX is a health research network that connects drug discovery and development from pharmaceutical companies.

Analytics · Cambridge$40.0M Series D
Blade Therapeutics
November 2018

Blade Therapeutics is a discovery stage drug development company.

Biopharma · South San FranciscoSeries Unknown
Tetherex Pharmaceuticals
April 2018

Tetherex Pharmaceuticals operates in the healthcare industry focusing on biotechnology business.

Biotechnology · Oklahoma City$50.0M Series B
Aratana Therapeutics
March 2018

Aratana Therapeutics develops innovative therapies for the animal health industry.

Biotechnology · Leawood$11.7M Post Ipo Equity
Maverick Therapeutics
January 2017

Maverick Therapeutics is a biotech company focused on improving the lives of patients with solid tumor cancers

Biotechnology · Brisbane$125.0M Series Unknown
Atopix Therapeutics
November 2016

Atopix Therapeutics Limited is a privately held, clinical-stage, biopharmaceutical company based in Oxford, UK

Biotechnology · AbingdonSeries Unknown
Raze Therapeutics
October 2014

Raze Therapeutics, Inc., a biotechnology company, engages in the discovery and development of oncology therapeutics.

Biotechnology · Cambridge$24.0M Series A
Sideris Pharmaceuticals
October 2013

Sideris Pharmaceuticals is focused on the development of therapeutics for the treatment of transfusion-related iron overload.

Biotechnology · Lexington$32.0M Series A
CoStim Pharmaceuticals
March 2013

CoStim Pharmaceuticals Inc. operates as a biotechnology company. It develops antibody agents for treatment of cancer. The company was

Biotechnology · Boston$22.0M Series A

Where MPM Capital invests

Biotechnology21
Health Care11
Therapeutics11
Medical9
Pharmaceutical8
Life Science3

About MPM Capital's portfolio

How many companies has MPM Capital invested in?

MPM Capital has invested in 49 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does MPM Capital invest in?

MPM Capital's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 17 different industry categories.

What is MPM Capital's largest investment?

Among tracked funding rounds, ReNAgade Therapeutics received $300.0M in a Series A round. MPM Capital's total known invested capital is $3.9B.

What is the average investment size for MPM Capital?

MPM Capital's average investment size is $90.3M across its portfolio of 49 companies.

What are MPM Capital's most recent investments?

Recent MPM Capital portfolio additions include Firefly Bio, Deka Biosciences, AstronauTx, ReNAgade Therapeutics, Photys Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 49 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →